Stock Analysis

ContextVision Full Year 2024 Earnings: Beats Expectations

Published
OB:CONTX

ContextVision (OB:CONTX) Full Year 2024 Results

Key Financial Results

  • Revenue: kr139.2m (up 5.0% from FY 2023).
  • Net income: kr24.7m (down 25% from FY 2023).
  • Profit margin: 18% (down from 25% in FY 2023). The decrease in margin was driven by higher expenses.
  • EPS: kr0.32 (down from kr0.42 in FY 2023).
OB:CONTX Earnings and Revenue Growth February 22nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

ContextVision Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%.

Looking ahead, revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.

Performance of the market in Norway.

The company's shares are up 1.9% from a week ago.

Risk Analysis

You still need to take note of risks, for example - ContextVision has 2 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.